Relative Bioavailability and Bioequivalence of Opicapone

• Register: ClinicalTrials.gov
• Last refreshed on: 12 December 2020
• Main ID: NCT03820037
• Date of registration: 25/01/2019
• Prospective Registration: Yes
• Primary sponsor: Bial - Portela C S.A.
• Public title: Relative Bioavailability and Bioequivalence of Opicapone
• Scientific title: A Phase I, Open-Label, Randomised, Three-Period, Three-Sequence, Partial Replicate Crossover Study to Investigate the Relative Bioavailability and Bioequivalence of Opicapone Obtained From Two Different Sources, Under Fasting Conditions After Single-dose Administration in Healthy Subjects
• Date of first enrolment: March 2019
• Target sample size: 45
• Recruitment status: Not yet recruiting
• URL: https://clinicaltrials.gov/show/NCT03820037
• Study type: Interventional
• Study design: Allocation: Randomized. Intervention model: Crossover Assignment. Primary purpose: Treatment. Masking: None (Open Label).
• Phase: Phase 1

Countries of recruitment

United Kingdom

Contacts

• Name: João Ferreira, MSc

• Name: João Ferreira, MSc

Key inclusion & exclusion criteria

Inclusion Criteria:

1. Males or females, between 18 and 55 years of age, inclusive.

2. Body mass index (BMI) between 18.0 and 30.0 kg/m2, inclusive.

3. Healthy subjects as determined by no clinically significant findings from medical
history, physical examination, complete neurological examination, 12 lead ECG, vital
signs measurements, and clinical laboratory evaluations (congenital nonhaemolytic
hyperbilirubinemia [eg, suspicion of Gilbert's syndrome based on total and direct
bilirubin] is not acceptable) at Screening and Check in as assessed by the
Investigator (or designee).

4. Females will not be pregnant (i.e. the the pregnancy test at screening and at
admission to each treatment period must be negative), or lactating, and females of
childbearing potential and males will agree to use contraception.

5. Able to comprehend and willing to sign and date an Informed Consent Form (ICF) before
any study-specific screening procedure is performed, and to abide by the study
restrictions.

Exclusion Criteria:

1. Significant history or clinical manifestation of any metabolic, allergic,
dermatological, hepatic, renal, haematological, lymphatic, cardiovascular,
gastrointestinal, neurological, respiratory, endocrine, genitourinary, immunological,
connective tissue diseases or disorders, musculoskeletal, psychiatric disorder, or
have a clinically relevant surgical history as determined by the Investigator (or
designee).

2. History of significant hypersensitivity, intolerance, or allergy to any drug compound,
food, or other substance, unless approved by the Investigator (or designee).

3. History of febrile illness within 10 days prior to the each dose of study drug, or
subjects with evidence of active infection

4. Acute gastrointestinal symptoms (eg nausea, vomiting, diarrhoea, heartburn) as
determined by the Investigator (or designee).

5. Significantly impaired hepatic function, defined as any of the following (confirmed by
repeat):

1. Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x
upper limit of normal (ULN)

2. Total bilirubin (TBL) > 2 x ULN

6. Significant personal or family history of haemostatic disorders

7. History of galactose intolerance (eg the Lapp lactase deficiency or glucose-galactose
malabsorption)

8. Symptomatic orthostatic hypotension (drop of > 20 mmHg in systolic blood pressure
and/or > 10 mmHg in diastolic blood pressure) when moving from supine to standing
position, together with other symptoms, e.g., dizziness.

9. History of stomach or intestinal surgery or resection that would potentially alter
absorption and/or excretion of orally administered drugs (uncomplicated appendectomy
and hernia repair will be allowed).

10. History of alcoholism or drug/chemical abuse within 2 years prior to Check in to the
first treatment period.

11. Alcohol consumption of >21 units per week for males and >14 units for females. One
unit of alcohol equals ½ pint (285 mL) of beer or lager, 1 glass (125 mL) of wine, or
1/6 gill (25 mL) of spirits.

12. Positive alcohol breath test result or positive urine drug screen (confirmed by
repeat) at Screening or Check in to each treatment period.

13. Positive hepatitis panel and/or positive human immunodeficiency virus test

14. Participation in a clinical study involving administration of an investigational drug
(new chemical entity) in the past 90 days prior to first dose of study drug.

15. Use or intend to use any medications/products known to alter drug absorption,
metabolism, or elimination processes, including St. John's wort, within 30 days prior
to Check-in of the first treatment period, unless deemed acceptable by the
Investigator (or designee).

16. Use or intend to use any prescription medications/products within 14 days prior to
dosing, unless deemed acceptable by the Investigator (or designee).

17. Use or intend to use slow release medications/products considered to still be active
within 14 days prior to Check in, unless deemed acceptable by the Investigator (or
designee).

18. Use or intend to use any nonprescription medications/products including vitamins,
minerals, and phytotherapeutic/herbal/plant derived preparations within 7 days prior
to Check in, unless deemed acceptable by the Investigator (or designee).

19. Use of tobacco or nicotine containing products within 3 months prior to Check in, or
positive cotinine at Screening or Check-in.

20. Receipt of blood products within 2 months prior to Check in.

21. Donation of blood from 3 months prior to Screening, plasma from 2 weeks prior to
Screening, or platelets from 6 weeks prior to Screening.

22. Subjects who are vegetarians, vegans or have medical dietary restrictions

23. Poor peripheral venous access.

24. Have previously completed or withdrawn from this study or any other study
investigating opicapone, and have previously received the investigational product.

25. Subjects who, in the opinion of the Investigator (or designee), should not participate
in this study



Age minimum: 18 Years
Age maximum: 55 Years
Gender: All

Health Condition(s) or Problem(s) studied

Parkinson Disease

Intervention(s)

Drug: BIA 9-1067 (test)

Drug: Ongentys

Primary Outcome(s)

area under the plasma concentration-time curve from time zero to the last observable concentration at time t (AUC0 t) [Time Frame: Day 1 up to day 14]

area under the plasma concentration-time curve from time zero to infinity (AUC0 8) [Time Frame: Day 1 up to day 14]

maximum observed plasma concentration (Cmax) [Time Frame: Day 1 up to day 14]

Secondary ID(s)

BIA-91067-132

Source(s) of Monetary Support

Please refer to primary and secondary sponsors